Literature DB >> 12477806

Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.

Francois Villinger1, Ann E Mayne, Pavel Bostik, Kazuyasu Mori, Peter E Jensen, Rafi Ahmed, Aftab A Ansari.   

Abstract

By using the dominant simian immunodeficiency virus (SIV) Gag Mamu-A01 restricted major histocompatibility complex (MHC) class I epitope p11CM, we demonstrate antibody-mediated enhanced MHC class I cross presentation of SIV Gag. In vitro restimulation of peripheral blood mononuclear cells from SIV-infected rhesus macaques with recombinant full-length SIV Gag p55 plus p55 affinity-purified immunoglobulin G (p55 Gag/p55-IgG) led to the generation of markedly higher frequencies of p11CM specific precursor cytotoxic T lymphocytes (p-CTLs) compared with restimulation with (i) SIV Gag p55 alone or (ii) optimal concentrations of the p11CM peptide alone. These results, along with the finding that CD4 depletion abrogated the enhancement, suggest a prominent role for CD4(+) T cells. Testing for p-CTLs against other Mamu-A01-restricted SIV Gag epitopes suggested that this mechanism favored recognition of the dominant p11CM peptide, potentially further skewing of the CTL response. The p-CTL enhancing effect was also decreased or abrogated by pepsin digestion of the p55-specific IgG or by the addition of monoclonal antibodies to Fc receptor (FcR) II/III, suggesting that the effect was dependent on FcR-mediated uptake of the immune-complexed antigen. Finally, incubation of antigen-presenting cells with SIV Gag p55 immune complexes in the presence of lactacystin or of bafilomycin indicated that the mechanism of antibody-mediated enhancement of cross presentation required both the proteasomal and the endosomal pathways. These data demonstrate for the first time the cross presentation of antigens via immune complexes in lentiviral infection and indicate a heretofore-unrecognized role for antibodies in modulating the magnitude and potentially also the breadth of MHC class I-restricted antigen processing and presentation and CTL responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477806      PMCID: PMC140624          DOI: 10.1128/jvi.77.1.10-24.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Failure to expand influenza and tetanus toxoid memory T cells in vitro correlates with disease course in SIV infected rhesus macaques.

Authors:  A A Ansari; P Bostik; A E Mayne; F Villinger
Journal:  Cell Immunol       Date:  2001-06-15       Impact factor: 4.868

2.  Optimized insect cell culture for the production of recombinant heterologous proteins and baculovirus particles.

Authors:  C A Pereira; Y Pouliquen; V Rodas; D Massotte; C Mortensen; M C Sogayar; J Ménissier-de Murcia
Journal:  Biotechniques       Date:  2001-12       Impact factor: 1.993

3.  Major histocompatibility complex class I presentation of ovalbumin peptide 257-264 from exogenous sources: protein context influences the degree of TAP-independent presentation.

Authors:  M J Wick; J D Pfeifer
Journal:  Eur J Immunol       Date:  1996-11       Impact factor: 5.532

4.  Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

Authors:  P L Earl; W Sugiura; D C Montefiori; C C Broder; S A Lee; C Wild; J Lifson; B Moss
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 5.  Cytotoxic T lymphocytes specific for the simian immunodeficiency virus.

Authors:  N L Letvin; J E Schmitz; H L Jordan; A Seth; V M Hirsch; K A Reimann; M J Kuroda
Journal:  Immunol Rev       Date:  1999-08       Impact factor: 12.988

6.  Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection.

Authors:  D C Montefiori; T S Hill; H T Vo; B D Walker; E S Rosenberg
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

7.  Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques.

Authors:  A Gallimore; M Cranage; N Cook; N Almond; J Bootman; E Rud; P Silvera; M Dennis; T Corcoran; J Stott
Journal:  Nat Med       Date:  1995-11       Impact factor: 53.440

8.  Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.

Authors:  G Fenteany; R F Standaert; W S Lane; S Choi; E J Corey; S L Schreiber
Journal:  Science       Date:  1995-05-05       Impact factor: 47.728

9.  Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1.

Authors:  J York; K E Follis; M Trahey; P N Nyambi; S Zolla-Pazner; J H Nunberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

10.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.

Authors:  M J Bevan
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Antibody-mediated immunomodulation: a strategy to improve host responses against microbial antigens.

Authors:  L Jeannine Brady
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 2.  Structural genomics of protein phosphatases.

Authors:  Steven C Almo; Jeffrey B Bonanno; J Michael Sauder; Spencer Emtage; Teresa P Dilorenzo; Vladimir Malashkevich; Steven R Wasserman; S Swaminathan; Subramaniam Eswaramoorthy; Rakhi Agarwal; Desigan Kumaran; Mahendra Madegowda; Sugadev Ragumani; Yury Patskovsky; Johnjeff Alvarado; Udupi A Ramagopal; Joana Faber-Barata; Mark R Chance; Andrej Sali; Andras Fiser; Zhong-yin Zhang; David S Lawrence; Stephen K Burley
Journal:  J Struct Funct Genomics       Date:  2007-12-05

3.  Quantitative MRI Measures in SIV-Infected Macaque Brains.

Authors:  Xiaodong Zhang; Chunxia Li
Journal:  J Clin Cell Immunol       Date:  2013

Review 4.  Molecular Pharming: future targets and aspirations.

Authors:  Mathew Paul; Craig van Dolleweerd; Pascal M W Drake; Rajko Reljic; Harry Thangaraj; Tommaso Barbi; Elena Stylianou; Ilaria Pepponi; Leonard Both; Verena Hehle; Luisa Madeira; Varghese Inchakalody; Sammy Ho; Thais Guerra; Julian K-C Ma
Journal:  Hum Vaccin       Date:  2011-03-01

5.  Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.

Authors:  Ussama Abdel-Motal; Shixia Wang; Shan Lu; Kim Wigglesworth; Uri Galili
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Influence of glycosylation on the efficacy of an Env-based vaccine against simian immunodeficiency virus SIVmac239 in a macaque AIDS model.

Authors:  Kazuyasu Mori; Chie Sugimoto; Shinji Ohgimoto; Emi E Nakayama; Tatsuo Shioda; Shigeru Kusagawa; Yutaka Takebe; Munehide Kano; Tetsuro Matano; Takae Yuasa; Daisuke Kitaguchi; Masaaki Miyazawa; Yumiko Takahashi; Michio Yasunami; Akinori Kimura; Naoki Yamamoto; Yasuo Suzuki; Yoshiyuki Nagai
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

7.  The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge.

Authors:  Leandro J Carreño; Susan M Bueno; Paulina Bull; Stanley G Nathenson; Alexis M Kalergis
Journal:  Immunology       Date:  2007-02-20       Impact factor: 7.397

Review 8.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

9.  A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy.

Authors:  Henri-Alexandre Michaud; Tiphanie Gomard; Laurent Gros; Kevin Thiolon; Roudaina Nasser; Chantal Jacquet; Javier Hernandez; Marc Piechaczyk; Mireia Pelegrin
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

10.  Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever.

Authors:  Juan D Rodas; Igor S Lukashevich; Juan C Zapata; Cristiana Cairo; Ilia Tikhonov; Mahmoud Djavani; C David Pauza; Maria S Salvato
Journal:  J Med Virol       Date:  2004-03       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.